Terms: = Endocrine gland cancer AND ERBB2, c-erb B2, 2064, P04626, ENSG00000141736, c-erbB2, HER-2/neu, HER2, TKR1, NEU, NGL, HER-2 AND Staging
24 results:
1. Clinicopathological pattern of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 over-expression of epithelial ovarian carcinomas in Nigeria.
Ajani MA; Lawan A; Oke T; Khramtsova G; Nwanji I; Salami A; Awolude O; Ebili H; Onwukamuche ME; Sveen E; Yoshimatsu T; Olopade OI
Afr Health Sci; 2023 Sep; 23(3):236-244. PubMed ID: 38357171
[TBL] [Abstract] [Full Text] [Related]
2. This house believes that: MARI/TAD is better than sentinel node biopsy after PST for cN+ patients.
van Hemert AKE; van Duijnhoven FH; Vrancken Peeters MTFD
Breast; 2023 Oct; 71():89-95. PubMed ID: 37562108
[TBL] [Abstract] [Full Text] [Related]
3. Gastric Amphicrine Carcinoma Showing neuroendocrine and Pancreatic Acinar Cell Differentiation. Lesson from a Challenging Case Opening New Perspectives in the Diagnostic Work-Up of Gastric neuroendocrine Neoplasms.
Sciarra A; Uccella S; Hiroz P; Fournier I; Soubeyran V; Finzi G; La Rosa S
Endocr Pathol; 2023 Sep; 34(3):349-357. PubMed ID: 37249796
[TBL] [Abstract] [Full Text] [Related]
4. Expanding Criteria for Prognostic Stage IA in Hormone Receptor-Positive Breast cancer.
Kantor O; King TA; Shak S; Russell CA; Giuliano AE; Hortobagyi GN; Burstein HJ; Winer EP; Dey T; Sparano JA; Mittendorf EA
J Natl Cancer Inst; 2021 Nov; 113(12):1744-1750. PubMed ID: 34010423
[TBL] [Abstract] [Full Text] [Related]
5. her2-positive pure mucinous breast carcinoma: A case report and literature review.
Zhao X; Yang X; Gao R; Zhai L; Yang L; Yu K
Medicine (Baltimore); 2020 Aug; 99(33):e20996. PubMed ID: 32871976
[TBL] [Abstract] [Full Text] [Related]
6. When a metastatic breast cancer is mimicking a pancreatic cancer: case report and review of the literature.
Derouane F; Yombi JC; Baurain JF; Danse E; Komuta M; Yildiz H
Acta Clin Belg; 2020 Aug; 75(4):301-307. PubMed ID: 31035903
[TBL] [Abstract] [Full Text] [Related]
7. Prevalence of breast and ovarian cancer subtypes in Hispanic populations from Puerto Rico.
Rodriguez-Velazquez A; Velez R; Lafontaine JC; Colon-Echevarria CB; Lamboy-Caraballo RD; Ramirez I; Mendoza A; Casbas-Hernandez P; Armaiz-Pena GN
BMC Cancer; 2018 Nov; 18(1):1177. PubMed ID: 30482165
[TBL] [Abstract] [Full Text] [Related]
8. Expressions of fatty acid synthase and her2 are correlated with poor prognosis of ovarian cancer.
Cai Y; Wang J; Zhang L; Wu D; Yu D; Tian X; Liu J; Jiang X; Shen Y; Zhang L; Ren M; Huang P
Med Oncol; 2015 Jan; 32(1):391. PubMed ID: 25433947
[TBL] [Abstract] [Full Text] [Related]
9. Phosphorylation of STAT3 correlates with her2 status, but not with survival in pancreatic ductal adenocarcinoma.
Koperek O; Aumayr K; Schindl M; Werba G; Soleiman A; Schoppmann S; Sahora K; Birner P
APMIS; 2014 Jun; 122(6):476-81. PubMed ID: 24164699
[TBL] [Abstract] [Full Text] [Related]
10. Changes and prognostic value of serum vascular endothelial growth factor in patients with differentiated thyroid cancer.
Zhou ZH; Cui XN; Xing HG; Yan RH; Yao DK; Wang LX
Med Princ Pract; 2013; 22(1):24-8. PubMed ID: 22890443
[TBL] [Abstract] [Full Text] [Related]
11. [Prognostic value of clinical, histopathological and immunohistochemical features in medullary thyroid cancer].
Ríos A; Rodríguez JM; Febrero B; Acosta JM; Torregrosa N; Parrilla P
Med Clin (Barc); 2012 Sep; 139(7):277-83. PubMed ID: 22032817
[TBL] [Abstract] [Full Text] [Related]
12. Changing pathology with changing drugs: tumors of the gastrointestinal tract.
Cervera P; Fléjou JF
Pathobiology; 2011; 78(2):76-89. PubMed ID: 21677471
[TBL] [Abstract] [Full Text] [Related]
13. Immune modulator CD70 as a potential cisplatin resistance predictive marker in ovarian cancer.
Aggarwal S; He T; Fitzhugh W; Rosenthal K; Feild B; Heidbrink J; Mesmer D; Ruben SM; Moore PA
Gynecol Oncol; 2009 Dec; 115(3):430-7. PubMed ID: 19800108
[TBL] [Abstract] [Full Text] [Related]
14. Adrenocortical tumors in Brazilian children: immunohistochemical markers and prognostic factors.
Sbragia L; Oliveira-Filho AG; Vassallo J; Pinto GA; Guerra-Junior G; Bustorff-Silva J
Arch Pathol Lab Med; 2005 Sep; 129(9):1127-31. PubMed ID: 16119984
[TBL] [Abstract] [Full Text] [Related]
15. Quantitative immuno-positron emission tomography imaging of her2-positive tumor xenografts with an iodine-124 labeled anti-her2 diabody.
Robinson MK; Doss M; Shaller C; Narayanan D; Marks JD; Adler LP; González Trotter DE; Adams GP
Cancer Res; 2005 Feb; 65(4):1471-8. PubMed ID: 15735035
[TBL] [Abstract] [Full Text] [Related]
16. Immunohistochemistry can help distinguish metastatic pancreatic adenocarcinomas from bile duct adenomas and hamartomas of the liver.
Hornick JL; Lauwers GY; Odze RD
Am J Surg Pathol; 2005 Mar; 29(3):381-9. PubMed ID: 15725808
[TBL] [Abstract] [Full Text] [Related]
17. Clinical and biological characteristics of clear cell carcinomas of the ovary in FIGO stages I-II.
Skírnisdóttir I; Seidal T; Karlsson MG; Sorbe B
Int J Oncol; 2005 Jan; 26(1):177-83. PubMed ID: 15586238
[TBL] [Abstract] [Full Text] [Related]
18. Analysis of potential prognostic factors in 111 patients with ovarian cancer.
Hornung R; Urs E; Serenella E; Edward W; Ursula S; Urs H; Daniel F
Cancer Lett; 2004 Mar; 206(1):97-106. PubMed ID: 15019165
[TBL] [Abstract] [Full Text] [Related]
19. FISH analysis of BRCA1 copy number in paraffin-embedded ovarian cancer tissue samples.
Kato H; Arakawa A; Suzumori K; Kataoka N; Young SR
Exp Mol Pathol; 2004 Apr; 76(2):138-42. PubMed ID: 15010292
[TBL] [Abstract] [Full Text] [Related]
20. Immunohistochemical evaluation is not prognostic for recurrence in fully staged high-risk endometrial cancer.
Fanning J; Brown S; Phibbs G; Kramer T; Zaher A
Int J Gynecol Cancer; 2002; 12(3):286-9. PubMed ID: 12060450
[TBL] [Abstract] [Full Text] [Related]
[Next]
